» Articles » PMID: 37976400

A Multicellular Liver Organoid Model for Investigating Hepatitis C Virus Infection and Nonalcoholic Fatty Liver Disease Progression

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2023 Nov 17
PMID 37976400
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: HCV infection can be successfully managed with antiviral therapies; however, progression to chronic liver disease states, including NAFLD, is common. There is currently no reliable in vitro model for investigating host-viral interactions underlying the link between HCV and NAFLD; although liver organoids (LOs) show promise, they currently lack nonparenchymal cells, which are key to modeling disease progression.

Approach And Results: Here, we present a novel, multicellular LO model using a coculture system of macrophages and LOs differentiated from the same human pluripotent stem cells (PSCs). The cocultured macrophages shifted toward a Kupffer-like cell type, the liver-resident macrophages present in vivo , providing a suitable model for investigating NAFLD pathogenesis. With this multicellular Kupffer-like cell-containing LO model, we found that HCV infection led to lipid accumulation in LOs by upregulating host lipogenesis, which was more marked with macrophage coculture. Reciprocally, long-term treatment of LOs with fatty acids upregulated HCV amplification and promoted inflammation and fibrosis. Notably, in our Kupffer-like cell-containing LO model, the effects of 3 drugs for NASH that have reached phase 3 clinical trials exhibited consistent results with the clinical outcomes.

Conclusions: Taken together, we introduced a multicellular LO model consisting of hepatocytes, Kupffer-like cells, and HSCs, which recapitulated host-virus intercommunication and intercellular interactions. With this novel model, we present a physiologically relevant system for the investigation of NAFLD progression in patients with HCV.

Citing Articles

Global landscape of hepatic organoid research: A bibliometric and visual study.

Li T, Bo R, Yan J, Johnson N, Liao M, Li Y World J Hepatol. 2025; 17(2):95624.

PMID: 40027550 PMC: 11866153. DOI: 10.4254/wjh.v17.i2.95624.


Current hPSC-derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism.

Kim H, Park H Toxicol Res. 2025; 41(2):105-121.

PMID: 40013078 PMC: 11850699. DOI: 10.1007/s43188-024-00275-8.


Islet organoids: a new hope for islet transplantation in diabetes.

Yu X, Liu C, Kuang Z, Song S, Tian L, Wang Y Front Immunol. 2025; 15:1540209.

PMID: 39906747 PMC: 11790636. DOI: 10.3389/fimmu.2024.1540209.


Transcriptomic and proteomic sequencing unveils the role of vitamin D and metabolic flux shifts in the induction of human hepatic organoids.

Zhang S, Liu L, Li X, Zhou T, Shi Q, Li D Stem Cell Res Ther. 2024; 15(1):478.

PMID: 39696644 PMC: 11657659. DOI: 10.1186/s13287-024-04101-8.


Development of Liver Cancer Organoids: Reproducing Tumor Microenvironment and Advancing Research for Liver Cancer Treatment.

Li K, Ren K, Du S, Gao X, Yu J Technol Cancer Res Treat. 2024; 23:15330338241285097.

PMID: 39363866 PMC: 11456184. DOI: 10.1177/15330338241285097.